GIP and Obesity: In the SURMOUNT-1 trial, which investigated the effects of the dual GIP/GLP-1 receptor agonist tirzepatide on body composition in individuals with obesity or overweight, it was found that 75% of weight loss was attributable to fat mass and 25% to lean mass with no significant difference compared to placebo [31].